Država: Kanada
Jezik: angleščina
Source: Health Canada
ZOLMITRIPTAN
JAMP PHARMA CORPORATION
N02CC03
ZOLMITRIPTAN
2.5MG
TABLET
ZOLMITRIPTAN 2.5MG
ORAL
6
Prescription
SELECTIVE SEROTONIN AGONISTS
Active ingredient group (AIG) number: 0134381001; AHFS:
APPROVED
2014-03-07
Page | 1 PRODUCT MONOGRAPH PR JAMP-ZOLMITRIPTAN ZOLMITRIPTAN TABLETS 2.5 MG 5-HT 1 Receptor Agonist MIGRAINE THERAPY JAMP Pharma Corporation Date of Revision: 1310 rue Nobel July 13, 2020 Boucherville, Québec J4B 5H3, Canada Control #240556 Page | 2 TABLE OF CONTENTS PRODUCT MONOGRAPH ...................................................................................................... 1 TABLE OF CONTENTS .......................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION ......................................................... 3 SUMMARY PRODUCT INFORMATION .......................................................................... 3 INDICATIONS AND CLINICAL USE ................................................................................ 3 CONTRAINDICATIONS ..................................................................................................... 4 WARNINGS AND PRECAUTIONS .................................................................................... 4 ADVERSE REACTIONS .................................................................................................... 11 DRUG INTERACTIONS .................................................................................................... 18 DOSAGE AND ADMINISTRATION ................................................................................ 19 OVERDOSAGE .................................................................................................................. 20 ACTION AND CLINICAL PHARMACOLOGY .............................................................. 21 STORAGE AND STABILITY ............................................................................................ 24 DOSAGE FORMS, COMPOSITION AND PACKAGING ............................................... 24 PART II: SCIENTIFIC INFORMATION ............................................................................... 25 PHARMACEUTICAL INFORMATION ............................................. Preberite celoten dokument